BeiGene Explains The Landscape Of Oncology Trials In Brazil
Bridging the Gap: BeiGene’s Commitment to Advancing oncology Care in Brazil
Table of Contents
By Lígia Campos, Director, Clinical Operations Head brazil and LATAM, BeiGene
250-nationalhealthcaresystembrazilgettyimages536190941.jpg” title=”National Healthcare system brazil-GettyImages-536190941″/>With a population exceeding 203 million, Brazil faces important challenges in the fight against cancer. Disparities in care, socioeconomic factors, and limited access to advanced treatments create barriers for many patients. Recognizing these challenges, BeiGene established a dedicated local clinical operations team in brazil in mid-2022. This commitment to patient-centered care has already yielded extraordinary results: in just two years, the team launched over 10 clinical studies, enrolling more than 200 patients.
This success story is a testament to the team’s adaptability, operational excellence, and strategic vision for Brazil. By collaborating closely with principal investigators, clinical sites, and regulators, BeiGene has streamlined study start-up and approval processes. Leveraging a CRO-free operational model has driven cost efficiency and accelerated trial timelines, solidifying Brazil’s position as a critical hub for oncology research in Latin America.
This two-part series delves into BeiGene’s impact in Brazil. Part one explores the prevalence and treatment approaches for cancer in Brazil, highlighting both the benefits and challenges of conducting clinical trials in the country.
Understanding Cancer Prevalence and Treatment in Brazil
Brazil, the fifth moast populous country globally, boasts a diverse population where 45.3% identify as ”mixed-race” or “pardo.” The Brazilian National Cancer Institute (INCA) projects over 704,000 new cancer cases annually from 2023 to 2025, excluding non-melanoma skin cancers.While Brazilian patients receiving timely and appropriate treatment achieve outcomes comparable to those in high-income countries, significant disparities exist. Patients relying on public healthcare often experience shorter disease-free survival compared to those with private insurance.
Educational and socioeconomic factors also play a role. Lower educational attainment is frequently enough linked to poorer health literacy and delays in seeking medical care, further exacerbated by longer intervals between symptom onset and the first medical consultation.
Ethnic and racial disparities persist as well.Even when adjusted for income, studies indicate that Black and brown women have substantially lower 10-year survival rates for breast cancer compared to white women. This disparity is partly due to a higher proportion of advanced-stage diagnoses among Black and brown women.Moreover, cancer mortality rates in Latin America are approximately double those in the United States, making cancer the second leading cause of death in the region. Effective cancer management requires a multidisciplinary approach and increasingly relies on precision therapies, both of which pose significant challenges in low- and middle-income countries.In part two of this series, we will explore how BeiGene’s innovative approach is addressing these challenges and transforming the landscape of oncology care in Brazil.
Brazil: A Rising Star in Global Oncology Research
Despite a high cancer burden, Brazil faces hurdles in clinical trial participation. Experts say increased physician engagement and patient education are key to unlocking the country’s vast potential in oncology research.
Brazil, with its large population and growing healthcare needs, is a country grappling with a significant cancer burden.Yet, despite this pressing need for innovative treatments, physician participation in clinical trials remains surprisingly low.
A recent report by the Latin American Cooperative oncology Group (LACOG) sheds light on this paradox. While Brazil boasts a robust healthcare infrastructure and a pool of highly skilled medical professionals, several factors hinder its full potential in clinical research.
Limited access to clinical trials, bureaucratic hurdles, and a shortage of dedicated research staff are cited as major obstacles.
“There’s a clear need to increase physician engagement and educate patients about the benefits of participating in clinical trials,” says Dr. [Insert name], a leading oncologist in Brazil.”This will not only help advance cancer research but also provide patients with access to cutting-edge treatments.”
Brazil’s Untapped Potential
Despite these challenges, Brazil possesses several key advantages that make it an attractive destination for global clinical trials.
The country has a proven track record of accomplished trial recruitment, a well-trained medical workforce, and a supportive regulatory environment.
Furthermore, Brazil’s commitment to technological advancements, including the development of specialized technology parks, further strengthens its position as a hub for clinical research.
“Brazil has all the ingredients to become a global leader in oncology research,” says [Insert Name], a representative from BeiGene, a global biotechnology company committed to developing innovative cancer therapies. “By addressing the existing barriers and fostering collaboration between researchers, clinicians, and patients, we can unlock the country’s immense potential.”
Cost-Effectiveness and Global Impact
Beyond its scientific and logistical advantages, Brazil offers a compelling economic proposition for clinical trial sponsors.
Studies indicate that conducting clinical trials in Brazil can be significantly more cost-effective compared to developed nations like the United states.This cost advantage, coupled with Brazil’s large and diverse patient population, makes it an attractive option for pharmaceutical companies seeking to accelerate drug development and make treatments more accessible globally.
Looking Ahead: A Collaborative Approach
To fully realize Brazil’s potential in oncology research, a multi-pronged approach is essential.
Strengthening research infrastructure, streamlining regulatory processes, and providing ongoing training and support for clinical investigators are crucial steps.
Equally crucial is raising awareness among patients about the benefits of participating in clinical trials.
By fostering a culture of collaboration and innovation, Brazil can pave the way for groundbreaking advancements in cancer treatment, not only for its own citizens but for patients worldwide.
In the next installment of this series, we will delve deeper into BeiGene’s experience establishing clinical operations in Brazil, highlighting the company’s commitment to expanding access to innovative cancer therapies in the region.
BeiGene Expands Clinical Footprint in Latin America with Seasoned Leader
Lígia Campos Brings Extensive experience to Drive Oncology Research in Brazil and LATAM
(City, State) – BeiGene, a global biotechnology company focused on developing innovative cancer therapies, announced today the appointment of Lígia Campos as Director, Clinical Operations Head for brazil and LATAM. Campos brings over 17 years of experience in clinical research and operations within the pharmaceutical industry, bolstering BeiGene’s commitment to expanding its clinical presence and delivering cutting-edge oncology treatments to patients in the region.
Campos joins BeiGene from Novartis Oncology, where she held leadership roles overseeing clinical operations, real-world evidence initiatives, and strategic evidence generation. Her expertise spans regulatory submissions, patient recruitment strategies, and building strong collaborations with key stakeholders across Latin America.
“Lígia’s deep understanding of the Latin American healthcare landscape and her proven track record in clinical operations make her an invaluable asset to our team,” said [Insert Name and Title of Relevant BeiGene Executive]. “Her leadership will be instrumental as we continue to advance our clinical development programs and bring innovative cancer therapies to patients in need across Brazil and LATAM.”
With a background in pharmacy, Campos has worked extensively in diverse therapeutic areas, with a particular focus on oncology. Her commitment to driving clinical trial efficiency and operational excellence aligns perfectly with BeiGene’s mission to develop and deliver transformative cancer treatments globally.
“I am thrilled to join BeiGene at such a pivotal time for the company,” said Campos.”I am passionate about advancing oncology research and believe BeiGene’s innovative pipeline has the potential to make a real difference in the lives of patients in Brazil and throughout Latin America.”
Bridging the gap: BeiGene’s Commitment to Advancing Oncology Care in Brazil
NewsDirectory3 exclusive Interview
Brazil faces a complex challenge in its fight against cancer. While the nation possesses a skilled medical workforce and a growing healthcare infrastructure, disparities in care and limited access to advanced treatments create barriers for countless patients. Recognizing these challenges, BeiGene, a global biotechnology company, established a dedicated local clinical operations team in Brazil in mid-2022. This strategic move has already yielded impressive results, demonstrating BeiGene’s commitment to patient-centered care and its vision for Brazil’s role in global oncology research.
To delve deeper into BeiGene’s impact and explore the landscape of oncology care in Brazil, NewsDirectory3 spoke with [Insert Name, Title], a leading expert in the field.
NewsDirectory3: Brazil is grappling with a significant cancer burden, yet physician participation in clinical trials remains relatively low. What are some of the key factors contributing to this situation?
[Expert Name]: You’re right, Brazil’s vast population and growing cancer incidence necessitate a robust clinical trial ecosystem.
several factors contribute to the lower physician engagement. These include:
Limited Access to Trials: Geographical disparities and a lack of widespread awareness about available trials restrict opportunities for many physicians and, consequently, their patients.
Bureaucratic Hurdles: navigating the regulatory approval process for clinical trials can be complex and time-consuming, deterring some researchers from participating.
Shortage of Dedicated Research Staff: A lack of adequately trained personnel dedicated to research activities hinders the smooth execution of clinical trials.
NewsDirectory3: Despite these challenges, brazil possesses immense potential in global oncology research. What are some of the country’s key strengths?
[Expert Name]: Brazil absolutely has the potential to become a global leader in oncology research. We have:
Proven Recruitment Capabilities: Brazil has a strong track record of triumphant patient recruitment for clinical trials.
A Well-Trained Medical workforce: the country boasts a pool of highly skilled oncologists and researchers.
Supportive Regulatory Surroundings: The Brazilian regulatory agency, ANVISA, is actively working to streamline the approval process for clinical trials.
Technological Advancements: The growth of specialized technology parks and a growing focus on innovation are further strengthening Brazil’s position as a hub for clinical research.
NewsDirectory3: How can we bridge the gap and unlock Brazil’s full potential in oncology research?
[Expert Name]:
Increase Physician Education and Engagement: Initiatives focused on educating physicians about the benefits of clinical trial participation and addressing their concerns about logistical and regulatory hurdles are crucial.
Empower patients Through Education: Raising patient awareness about clinical trials and their potential benefits can significantly increase enrollment rates.
Foster Collaboration:
Strengthening collaborations between academic institutions,industry partners,and government agencies is essential for leveraging resources and expertise.
Invest in Infrastructure: Supporting the development of dedicated clinical trial units and providing adequate training and resources for research staff is vital.
NewsDirectory3: What is BeiGene doing to address these challenges and contribute to the advancement of oncology care in Brazil?
[Expert Name]: BeiGene is playing a crucial role in advancing oncology care in Brazil. Their dedicated local team, established in 2022, has already:
Launched over 10 clinical studies in just two years, enrolling more than 200 patients.
Demonstrated adaptability and operational excellence by streamlining study start-up and approval processes through close collaboration with key stakeholders.
Leveraged a CRO-free operational model, driving cost efficiency and accelerating trial timelines.
This success highlights BeiGene’s commitment to making Brazil a critical hub for oncology research in Latin America.
NewsDirectory3: Thank you for sharing your insights,[Expert Name]. It’s clear that bridging the gap in oncology care in Brazil requires a multifaceted approach involving collaboration, education, and investment. BeiGene’s dedication to this mission is encouraging,and we look forward to witnessing the continued advancements in cancer treatment fueled by their efforts.
[Optional: Include closing remarks from BeiGene representative, reiterating their commitment and vision for the future.]
Stay tuned for Part 2 of our series, where we will explore BeiGene’s innovative approach to addressing the challenges faced by Brazilian patients and revolutionizing the landscape of oncology care in the country.